ID   RAG1_HUMAN              Reviewed;        1043 AA.
AC   P15918; E9PPC4; Q8IY72; Q8NER2;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 2.
DT   10-MAY-2017, entry version 192.
DE   RecName: Full=V(D)J recombination-activating protein 1;
DE            Short=RAG-1;
DE   AltName: Full=RING finger protein 74;
DE   Includes:
DE     RecName: Full=Endonuclease RAG1;
DE              EC=3.1.-.-;
DE   Includes:
DE     RecName: Full=E3 ubiquitin-protein ligase RAG1;
DE              EC=2.3.2.27;
DE     AltName: Full=RING-type E3 ubiquitin transferase RAG1 {ECO:0000305};
GN   Name=RAG1; Synonyms=RNF74;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-249.
RX   PubMed=2598259; DOI=10.1016/0092-8674(89)90760-5;
RA   Schatz D.G., Oettinger M.A., Baltimore D.;
RT   "The V(D)J recombination activating gene, RAG-1.";
RL   Cell 59:1035-1048(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   ARG-249.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION OF IMPORTIN ALPHA-1 BINDING DOMAIN.
RX   PubMed=8052633; DOI=10.1073/pnas.91.16.7633;
RA   Cortes P., Ye Z.-S., Baltimore D.;
RT   "RAG-1 interacts with the repeated amino acid motif of the human
RT   homologue of the yeast protein SRP1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:7633-7637(1994).
RN   [6]
RP   VARIANTS GLY-244 AND ARG-249.
RX   PubMed=8844221;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:2<191::AID-HUMU15>3.3.CO;2-8;
RA   Nomdedeu J.F., Lasa A., Seminago R., Rubiol E., Baiget M., Soler J.;
RT   "Two new variants of RAG-1 protein predicted by SSCP.";
RL   Hum. Mutat. 8:191-192(1996).
RN   [7]
RP   VARIANTS T(-)B(-)NK(+) SCID HIS-624; LYS-722; 774-GLU--PHE-1043 DEL;
RP   897-ARG--PHE-1043 DEL AND 938-TYR--PHE-1043 DEL, VARIANT VAL-156,
RP   CHARACTERIZATION OF VARIANT VAL-156, AND CHARACTERIZATION OF VARIANTS
RP   T(-)B(-)NK(+) SCID HIS-624; LYS-722 AND 938-TYR--PHE-1043 DEL.
RX   PubMed=8810255; DOI=10.1126/science.274.5284.97;
RA   Schwarz K., Gauss G.H., Ludwig L., Pannicke U., Li Z., Linder D.,
RA   Friedrich W., Seger R.A., Hansen-Hagge T.E., Desiderio S.,
RA   Lieber M.R., Bartram C.R.;
RT   "RAG mutations in human B cell-negative SCID.";
RL   Science 274:97-99(1996).
RN   [8]
RP   VARIANTS OS CYS-396; HIS-396; GLY-429; HIS-561; CYS-561; HIS-737 AND
RP   CYS-912.
RX   PubMed=9630231; DOI=10.1016/S0092-8674(00)81448-8;
RA   Villa A., Santagata S., Bozzi F., Giliani S., Frattini A., Imberti L.,
RA   Gatta L.B., Ochs H.D., Schwarz K., Notarangelo L.D., Vezzoni P.,
RA   Spanopoulou E.;
RT   "Partial V(D)J recombination activity leads to Omenn syndrome.";
RL   Cell 93:885-896(1998).
RN   [9]
RP   VARIANTS OS CYS-396 AND ARG-885.
RX   PubMed=10606976; DOI=10.1046/j.1365-2249.2000.01101.x;
RA   Wada T., Takei K., Kudo M., Shimura S., Kasahara Y., Koizumi S.,
RA   Kawa-Ha K., Ishida Y., Imashuku S., Seki H., Yachie A.;
RT   "Characterization of immune function and analysis of RAG gene
RT   mutations in Omenn syndrome and related disorders.";
RL   Clin. Exp. Immunol. 119:148-155(2000).
RN   [10]
RP   VARIANTS OS TYR-328; LEU-396; PRO-401; GLN-410; MET-433; VAL-435;
RP   VAL-444; HIS-474; TRP-507; CYS-522 SER-559; CYS-624; GLY-669; LEU-753
RP   AND GLN-975, AND VARIANT ILE-855.
RX   PubMed=11133745; DOI=10.1182/blood.V97.1.81;
RA   Villa A., Sobacchi C., Notarangelo L.D., Bozzi F., Abinun M.,
RA   Abrahamsen T.G., Arkwright P.D., Baniyash M., Brooks E.G.,
RA   Conley M.E., Cortes P., Duse M., Fasth A., Filipovich A.M.,
RA   Infante A.J., Jones A., Mazzolari E., Muller S.M., Pasic S.,
RA   Rechavi G., Sacco M.G., Santagata S., Schroeder M.L., Seger R.,
RA   Strina D., Ugazio A., Vaeliaho J., Vihinen M., Vogler L.B., Ochs H.,
RA   Vezzoni P., Friedrich W., Schwarz K.;
RT   "V(D)J recombination defects in lymphocytes due to RAG mutations:
RT   severe immunodeficiency with a spectrum of clinical presentations.";
RL   Blood 97:81-88(2001).
RN   [11]
RP   VARIANTS SER-559 AND 897-ARG--PHE-1043 DEL, AND CHARACTERIZATION OF
RP   VARIANTS SER-559 AND 897-ARG--PHE-1043 DEL.
RX   PubMed=11520796;
RA   Kumaki S., Villa A., Asada H., Kawai S., Ohashi Y., Takahashi M.,
RA   Hakozaki I., Nitanai E., Minegishi M., Tsuchiya S.;
RT   "Identification of anti-herpes simplex virus antibody-producing B
RT   cells in a patient with an atypical RAG1 immunodeficiency.";
RL   Blood 98:1464-1468(2001).
RN   [12]
RP   VARIANTS T-CMVA TRP-841 AND PRO-981.
RX   PubMed=16276422; DOI=10.1172/JCI25178;
RA   de Villartay J.-P., Lim A., Al-Mousa H., Dupont S.,
RA   Dechanet-Merville J., Coumau-Gatbois E., Gougeon M.-L., Lemainque A.,
RA   Eidenschenk C., Jouanguy E., Abel L., Casanova J.-L., Fischer A.,
RA   Le Deist F.;
RT   "A novel immunodeficiency associated with hypomorphic RAG1 mutations
RT   and CMV infection.";
RL   J. Clin. Invest. 115:3291-3299(2005).
RN   [13]
RP   VARIANTS CHIDG TRP-314; TRP-507; HIS-737; GLN-778 AND TRP-975, AND
RP   CHARACTERIZATION OF VARIANTS CHIDG TRP-314; TRP-507; HIS-737; GLN-778
RP   AND TRP-975.
RX   PubMed=18463379; DOI=10.1056/NEJMoa073966;
RA   Schuetz C., Huck K., Gudowius S., Megahed M., Feyen O., Hubner B.,
RA   Schneider D.T., Manfras B., Pannicke U., Willemze R., Knuechel R.,
RA   Goebel U., Schulz A., Borkhardt A., Friedrich W., Schwarz K.,
RA   Niehues T.;
RT   "An immunodeficiency disease with RAG mutations and granulomas.";
RL   N. Engl. J. Med. 358:2030-2038(2008).
RN   [14]
RP   VARIANTS T(-)B(-)NK(+) SCID MET-433; SER-559 AND HIS-624, AND VARIANTS
RP   OS HIS-396 AND PRO-401.
RX   PubMed=19912631; DOI=10.1186/1471-2350-10-116;
RA   Alsmadi O., Al-Ghonaium A., Al-Muhsen S., Arnaout R., Al-Dhekri H.,
RA   Al-Saud B., Al-Kayal F., Al-Saud H., Al-Mousa H.;
RT   "Molecular analysis of T-B-NK+ severe combined immunodeficiency and
RT   Omenn syndrome cases in Saudi Arabia.";
RL   BMC Med. Genet. 10:116-116(2009).
RN   [15]
RP   VARIANT CYS-474.
RX   PubMed=20956421; DOI=10.1542/peds.2009-3171;
RA   Avila E.M., Uzel G., Hsu A., Milner J.D., Turner M.L., Pittaluga S.,
RA   Freeman A.F., Holland S.M.;
RT   "Highly variable clinical phenotypes of hypomorphic RAG1 mutations.";
RL   Pediatrics 126:E1248-E1252(2010).
RN   [16]
RP   VARIANT OS GLN-454.
RX   PubMed=21624848; DOI=10.1016/j.clim.2011.04.011;
RA   Dalal I., Tasher D., Somech R., Etzioni A., Garti B.Z., Lev D.,
RA   Cohen S., Somekh E., Leshinsky-Silver E.;
RT   "Novel mutations in RAG1/2 and ADA genes in Israeli patients
RT   presenting with T-B-SCID or Omenn syndrome.";
RL   Clin. Immunol. 140:284-290(2011).
RN   [17]
RP   VARIANT OS TRP-699.
RX   PubMed=21771083; DOI=10.1111/j.1399-3038.2010.01126.x;
RA   Zhang Z.Y., Zhao X.D., Jiang L.P., Liu E.M., Cui Y.X., Wang M.,
RA   Wei H., Yu J., An Y.F., Yang X.Q.;
RT   "Clinical characteristics and molecular analysis of three Chinese
RT   children with Omenn syndrome.";
RL   Pediatr. Allergy Immunol. 22:482-487(2011).
RN   [18]
RP   VARIANT TYR-358, AND CHARACTERIZATION OF VARIANT TYR-358.
RX   PubMed=24996264; DOI=10.1016/j.jaci.2014.04.042;
RA   Abolhassani H., Wang N., Aghamohammadi A., Rezaei N., Lee Y.N.,
RA   Frugoni F., Notarangelo L.D., Pan-Hammarstroem Q., Hammarstroem L.;
RT   "A hypomorphic recombination-activating gene 1 (RAG1) mutation
RT   resulting in a phenotype resembling common variable
RT   immunodeficiency.";
RL   J. Allergy Clin. Immunol. 134:1375-1380(2014).
RN   [19]
RP   VARIANTS CYS-522; ARG-612 AND 897-ARG--PHE-1043 DEL.
RX   PubMed=25516070; DOI=10.1007/s10875-014-0121-5;
RA   Buchbinder D., Baker R., Lee Y.N., Ravell J., Zhang Y., McElwee J.,
RA   Nugent D., Coonrod E.M., Durtschi J.D., Augustine N.H.,
RA   Voelkerding K.V., Csomos K., Rosen L., Browne S., Walter J.E.,
RA   Notarangelo L.D., Hill H.R., Kumanovics A.;
RT   "Identification of patients with RAG mutations previously diagnosed
RT   with common variable immunodeficiency disorders.";
RL   J. Clin. Immunol. 35:119-124(2015).
RN   [20]
RP   VARIANTS ASP-375 AND CYS-474, AND CHARACTERIZATION OF VARIANT CYS-474.
RX   PubMed=28216420; DOI=10.1016/j.clim.2016.12.013;
RA   Schroeder C., Baerlecken N.T., Pannicke U., Doerk T., Witte T.,
RA   Jacobs R., Stoll M., Schwarz K., Grimbacher B., Schmidt R.E.,
RA   Atschekzei F.;
RT   "Evaluation of RAG1 mutations in an adult with combined
RT   immunodeficiency and progressive multifocal leukoencephalopathy.";
RL   Clin. Immunol. 179:1-7(2017).
CC   -!- FUNCTION: Catalytic component of the RAG complex, a multiprotein
CC       complex that mediates the DNA cleavage phase during V(D)J
CC       recombination. V(D)J recombination assembles a diverse repertoire
CC       of immunoglobulin and T-cell receptor genes in developing B and T-
CC       lymphocytes through rearrangement of different V (variable), in
CC       some cases D (diversity), and J (joining) gene segments. In the
CC       RAG complex, RAG1 mediates the DNA-binding to the conserved
CC       recombination signal sequences (RSS) and catalyzes the DNA
CC       cleavage activities by introducing a double-strand break between
CC       the RSS and the adjacent coding segment. RAG2 is not a catalytic
CC       component but is required for all known catalytic activities. DNA
CC       cleavage occurs in 2 steps: a first nick is introduced in the top
CC       strand immediately upstream of the heptamer, generating a 3'-
CC       hydroxyl group that can attack the phosphodiester bond on the
CC       opposite strand in a direct transesterification reaction, thereby
CC       creating 4 DNA ends: 2 hairpin coding ends and 2 blunt, 5'-
CC       phosphorylated ends. The chromatin structure plays an essential
CC       role in the V(D)J recombination reactions and the presence of
CC       histone H3 trimethylated at 'Lys-4' (H3K4me3) stimulates both the
CC       nicking and haipinning steps. The RAG complex also plays a role in
CC       pre-B cell allelic exclusion, a process leading to expression of a
CC       single immunoglobulin heavy chain allele to enforce clonality and
CC       monospecific recognition by the B-cell antigen receptor (BCR)
CC       expressed on individual B-lymphocytes. The introduction of DNA
CC       breaks by the RAG complex on one immunoglobulin allele induces
CC       ATM-dependent repositioning of the other allele to pericentromeric
CC       heterochromatin, preventing accessibility to the RAG complex and
CC       recombination of the second allele. In addition to its
CC       endonuclease activity, RAG1 also acts as an E3 ubiquitin-protein
CC       ligase that mediates monoubiquitination of histone H3. Histone H3
CC       monoubiquitination is required for the joining step of V(D)J
CC       recombination. Mediates polyubiquitination of KPNA1 (By
CC       similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC       Note=Binds 1 divalent metal cation per subunit. Mg(2+) or Mn(2+).
CC       {ECO:0000250};
CC   -!- SUBUNIT: Homodimer. Component of the RAG complex composed of core
CC       components RAG1 and RAG2, and associated component HMGB1 or HMGB2.
CC       Interacts with DCAF1, leading to recruitment of the CUL4A-RBX1-
CC       DDB1-DCAF1/VPRBP complex to ubiquitinate proteins and limit error-
CC       prone repair during V(D)J recombination (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       P16333:NCK1; NbExp=2; IntAct=EBI-1755109, EBI-389883;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00820}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P15918-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P15918-2; Sequence=VSP_055883;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Maturing lymphoid cells.
CC   -!- DOMAIN: The RING-type zinc finger mediates the E3 ubiquitin-
CC       protein ligase activity. {ECO:0000250}.
CC   -!- DOMAIN: The NBD (nonamer binding) DNA-binding domain mediates the
CC       specific binding to the nonamer RSS motif by forming a tightly
CC       interwoven homodimer that binds and synapses 2 nonamer elements,
CC       with each NBD making contact with both DNA molecules. Each RSS is
CC       composed of well-conserved heptamer (consensus 5'-CACAGTG-3') and
CC       nonamer (consensus 5'-ACAAAAACC-3') sequences separated by a
CC       spacer of either 12 bp or 23 bp. {ECO:0000255|PROSITE-
CC       ProRule:PRU00820}.
CC   -!- PTM: Autoubiquitinated in the presence of CDC34/UBCH3.
CC       {ECO:0000250}.
CC   -!- DISEASE: Combined cellular and humoral immune defects with
CC       granulomas (CHIDG) [MIM:233650]: Immunodeficiency disease with
CC       granulomas in the skin, mucous membranes, and internal organs.
CC       Other characteristics include hypogammaglobulinemia, a diminished
CC       number of T and B-cells, and sparse thymic tissue on
CC       ultrasonography. {ECO:0000269|PubMed:18463379}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Severe combined immunodeficiency autosomal recessive T-
CC       cell-negative/B-cell-negative/NK-cell-positive (T(-)B(-)NK(+)
CC       SCID) [MIM:601457]: A form of severe combined immunodeficiency
CC       (SCID), a genetically and clinically heterogeneous group of rare
CC       congenital disorders characterized by impairment of both humoral
CC       and cell-mediated immunity, leukopenia, and low or absent antibody
CC       levels. Patients present in infancy recurrent, persistent
CC       infections by opportunistic organisms. The common characteristic
CC       of all types of SCID is absence of T-cell-mediated cellular
CC       immunity due to a defect in T-cell development.
CC       {ECO:0000269|PubMed:19912631, ECO:0000269|PubMed:8810255}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Omenn syndrome (OS) [MIM:603554]: Severe immunodeficiency
CC       characterized by the presence of activated, anergic, oligoclonal
CC       T-cells, hypereosinophilia, and high IgE levels.
CC       {ECO:0000269|PubMed:10606976, ECO:0000269|PubMed:11133745,
CC       ECO:0000269|PubMed:19912631, ECO:0000269|PubMed:21624848,
CC       ECO:0000269|PubMed:21771083, ECO:0000269|PubMed:9630231}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Alpha/beta T-cell lymphopenia, with gamma/delta T-cell
CC       expansion, severe cytomegalovirus infection and autoimmunity (T-
CC       CMVA) [MIM:609889]: An immunological disorder characterized by
CC       oligoclonal expansion of TCR gamma/delta T-cells, TCR alpha/beta
CC       T-cell lymphopenia, severe, disseminated cytomegalovirus infection
CC       and autoimmune cytopenia. {ECO:0000269|PubMed:16276422}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the RAG1 family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00820}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAM77798.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/rag1/";
CC   -!- WEB RESOURCE: Name=RAG1base; Note=RAG1 deficiency database;
CC       URL="http://structure.bmc.lu.se/idbase/RAG1base/";
CC   -!- WEB RESOURCE: Name=Mendelian genes recombination activating gene 1
CC       (RAG1); Note=Leiden Open Variation Database (LOVD);
CC       URL="http://www.lovd.nl/RAG1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M29474; AAA60248.1; -; mRNA.
DR   EMBL; AY130302; AAM77798.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC061999; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC139427; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC037344; AAH37344.1; -; mRNA.
DR   CCDS; CCDS7902.1; -. [P15918-1]
DR   PIR; A33754; A33754.
DR   RefSeq; NP_000439.1; NM_000448.2.
DR   RefSeq; XP_005253098.1; XM_005253041.4. [P15918-1]
DR   RefSeq; XP_011518552.1; XM_011520250.2. [P15918-1]
DR   UniGene; Hs.538979; -.
DR   UniGene; Hs.677010; -.
DR   UniGene; Hs.73958; -.
DR   ProteinModelPortal; P15918; -.
DR   SMR; P15918; -.
DR   BioGrid; 111832; 25.
DR   IntAct; P15918; 14.
DR   MINT; MINT-1511469; -.
DR   STRING; 9606.ENSP00000299440; -.
DR   iPTMnet; P15918; -.
DR   PhosphoSitePlus; P15918; -.
DR   BioMuta; RAG1; -.
DR   DMDM; 313104166; -.
DR   PaxDb; P15918; -.
DR   PRIDE; P15918; -.
DR   Ensembl; ENST00000299440; ENSP00000299440; ENSG00000166349. [P15918-1]
DR   Ensembl; ENST00000534663; ENSP00000434610; ENSG00000166349. [P15918-2]
DR   GeneID; 5896; -.
DR   KEGG; hsa:5896; -.
DR   UCSC; uc001mwt.4; human. [P15918-1]
DR   CTD; 5896; -.
DR   DisGeNET; 5896; -.
DR   GeneCards; RAG1; -.
DR   HGNC; HGNC:9831; RAG1.
DR   MalaCards; RAG1; -.
DR   MIM; 179615; gene.
DR   MIM; 233650; phenotype.
DR   MIM; 601457; phenotype.
DR   MIM; 603554; phenotype.
DR   MIM; 609889; phenotype.
DR   neXtProt; NX_P15918; -.
DR   OpenTargets; ENSG00000166349; -.
DR   Orphanet; 231154; Combined immunodeficiency T+ B+ due to partial RAG1 deficiency.
DR   Orphanet; 157949; Combined immunodeficiency with skin granulomas.
DR   Orphanet; 39041; Omenn syndrome.
DR   Orphanet; 331206; Severe combined immunodeficiency due to complete RAG1/2 deficiency.
DR   PharmGKB; PA34185; -.
DR   eggNOG; ENOG410IKNG; Eukaryota.
DR   eggNOG; ENOG4110KH0; LUCA.
DR   GeneTree; ENSGT00390000008679; -.
DR   HOGENOM; HOG000232009; -.
DR   HOVERGEN; HBG003861; -.
DR   InParanoid; P15918; -.
DR   KO; K10628; -.
DR   OMA; IAKRFRY; -.
DR   OrthoDB; EOG091G00XO; -.
DR   PhylomeDB; P15918; -.
DR   TreeFam; TF331926; -.
DR   Reactome; R-HSA-1266695; Interleukin-7 signaling.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   SIGNOR; P15918; -.
DR   GenomeRNAi; 5896; -.
DR   PRO; PR:P15918; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000166349; -.
DR   CleanEx; HS_RAG1; -.
DR   Genevisible; P15918; HS.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0004519; F:endonuclease activity; ISS:UniProtKB.
DR   GO; GO:0042393; F:histone binding; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; ISS:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IEA:Ensembl.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; ISS:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; ISS:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEA:Ensembl.
DR   GO; GO:0030183; P:B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0006310; P:DNA recombination; TAS:ProtInc.
DR   GO; GO:0010390; P:histone monoubiquitination; ISS:UniProtKB.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0070244; P:negative regulation of thymocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0045582; P:positive regulation of T cell differentiation; IEA:Ensembl.
DR   GO; GO:0002331; P:pre-B cell allelic exclusion; ISS:UniProtKB.
DR   GO; GO:0051865; P:protein autoubiquitination; ISS:UniProtKB.
DR   GO; GO:0033077; P:T cell differentiation in thymus; ISS:UniProtKB.
DR   GO; GO:0043029; P:T cell homeostasis; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0033151; P:V(D)J recombination; IMP:CACAO.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 3.30.40.10; -; 3.
DR   InterPro; IPR024627; RAG1.
DR   InterPro; IPR019485; RAG1_Znf.
DR   InterPro; IPR023336; RAG_nonamer-bd_dom.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   InterPro; IPR018957; Znf_C3HC4_RING-type.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR11539; PTHR11539; 1.
DR   Pfam; PF12940; RAG1; 1.
DR   Pfam; PF00097; zf-C3HC4; 1.
DR   Pfam; PF10426; zf-RAG1; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF57667; SSF57667; 1.
DR   PROSITE; PS51487; NBD; 1.
DR   PROSITE; PS51765; ZF_RAG1; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Chromatin regulator; Complete proteome;
KW   Disease mutation; DNA recombination; DNA-binding; Endonuclease;
KW   Hydrolase; Isopeptide bond; Metal-binding; Multifunctional enzyme;
KW   Nuclease; Nucleus; Polymorphism; Reference proteome; SCID;
KW   Transferase; Ubl conjugation; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN         1   1043       V(D)J recombination-activating protein 1.
FT                                /FTId=PRO_0000056004.
FT   ZN_FING     293    332       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   ZN_FING     354    383       RAG1-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01101}.
FT   DNA_BIND    392    459       NBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00820}.
FT   REGION        1    288       Interaction with importin alpha-1.
FT   METAL       269    269       Zinc 1. {ECO:0000250}.
FT   METAL       273    273       Zinc 1. {ECO:0000250}.
FT   METAL       293    293       Zinc 2. {ECO:0000250}.
FT   METAL       296    296       Zinc 1. {ECO:0000250}.
FT   METAL       296    296       Zinc 2. {ECO:0000250}.
FT   METAL       298    298       Zinc 1. {ECO:0000250}.
FT   METAL       308    308       Zinc 3. {ECO:0000250}.
FT   METAL       310    310       Zinc 3. {ECO:0000250}.
FT   METAL       313    313       Zinc 2. {ECO:0000250}.
FT   METAL       316    316       Zinc 2. {ECO:0000250}.
FT   METAL       328    328       Zinc 3. {ECO:0000250}.
FT   METAL       331    331       Zinc 3. {ECO:0000250}.
FT   METAL       358    358       Zinc 4. {ECO:0000250}.
FT   METAL       363    363       Zinc 4. {ECO:0000250}.
FT   METAL       375    375       Zinc 4. {ECO:0000250}.
FT   METAL       379    379       Zinc 4. {ECO:0000250}.
FT   METAL       603    603       Divalent metal cation; catalytic.
FT                                {ECO:0000250}.
FT   METAL       711    711       Divalent metal cation; catalytic.
FT                                {ECO:0000250}.
FT   METAL       965    965       Divalent metal cation; catalytic.
FT                                {ECO:0000250}.
FT   SITE        896    896       Essential for DNA hairpin formation,
FT                                participates in base-stacking
FT                                interactions near the cleavage site.
FT                                {ECO:0000250}.
FT   CROSSLNK    234    234       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:P15919}.
FT   VAR_SEQ     931   1043       YEGKITNYFHKTLAHVPEIIERDGSIGAWASEGNESGNKLF
FT                                RRFRKMNARQSKCYEMEDVLKHHWLYTSKYLQKFMNAHNAL
FT                                KTSGFTMNPQASLGDPLGIEDSLESQDSMEF -> N (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_055883.
FT   VARIANT     156    156       A -> V (polymorphism; no effect on
FT                                recombination activity; dbSNP:rs1801203).
FT                                {ECO:0000269|PubMed:8810255}.
FT                                /FTId=VAR_007800.
FT   VARIANT     169    169       S -> L (in dbSNP:rs4151027).
FT                                /FTId=VAR_029260.
FT   VARIANT     244    244       R -> G (in dbSNP:rs199474683).
FT                                {ECO:0000269|PubMed:8844221}.
FT                                /FTId=VAR_007801.
FT   VARIANT     247    247       R -> H (in dbSNP:rs4151029).
FT                                /FTId=VAR_029261.
FT   VARIANT     249    249       H -> R (in dbSNP:rs3740955).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:2598259,
FT                                ECO:0000269|PubMed:8844221}.
FT                                /FTId=VAR_007802.
FT   VARIANT     302    302       D -> E (in dbSNP:rs4151030).
FT                                /FTId=VAR_020113.
FT   VARIANT     314    314       R -> W (in CHIDG; reduced recombination
FT                                activity; dbSNP:rs121918568).
FT                                {ECO:0000269|PubMed:18463379}.
FT                                /FTId=VAR_045957.
FT   VARIANT     328    328       C -> Y (in OS; dbSNP:rs121918571).
FT                                {ECO:0000269|PubMed:11133745}.
FT                                /FTId=VAR_025971.
FT   VARIANT     358    358       C -> Y (found in a patient with common
FT                                variable immunodeficiency with B cell
FT                                deficiency; decreased recombinant
FT                                activity). {ECO:0000269|PubMed:24996264}.
FT                                /FTId=VAR_078305.
FT   VARIANT     375    375       H -> D (found in a patient with T and B
FT                                cell immunodeficiency and progressive
FT                                multifocal leukoencephalopathy; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:28216420}.
FT                                /FTId=VAR_078306.
FT   VARIANT     396    396       R -> C (in OS; dbSNP:rs104894289).
FT                                {ECO:0000269|PubMed:10606976,
FT                                ECO:0000269|PubMed:9630231}.
FT                                /FTId=VAR_008886.
FT   VARIANT     396    396       R -> H (in OS; dbSNP:rs104894291).
FT                                {ECO:0000269|PubMed:19912631,
FT                                ECO:0000269|PubMed:9630231}.
FT                                /FTId=VAR_008887.
FT   VARIANT     396    396       R -> L (in OS; dbSNP:rs104894291).
FT                                {ECO:0000269|PubMed:11133745}.
FT                                /FTId=VAR_025972.
FT   VARIANT     401    401       S -> P (in OS; dbSNP:rs199474682).
FT                                {ECO:0000269|PubMed:11133745,
FT                                ECO:0000269|PubMed:19912631}.
FT                                /FTId=VAR_025973.
FT   VARIANT     410    410       R -> Q (in OS; found in patients with an
FT                                atypical form of severe combined
FT                                immunodeficiency/Omenn syndrome;
FT                                dbSNP:rs199474684).
FT                                {ECO:0000269|PubMed:11133745}.
FT                                /FTId=VAR_025974.
FT   VARIANT     429    429       D -> G (in OS; dbSNP:rs104894292).
FT                                {ECO:0000269|PubMed:9630231}.
FT                                /FTId=VAR_008888.
FT   VARIANT     433    433       V -> M (in OS and T(-)B(-)NK(+) SCID;
FT                                found in a patient with an atypical form
FT                                of severe combined immunodeficiency/Omenn
FT                                syndrome; dbSNP:rs199474679).
FT                                {ECO:0000269|PubMed:11133745,
FT                                ECO:0000269|PubMed:19912631}.
FT                                /FTId=VAR_025975.
FT   VARIANT     435    435       M -> V (in OS; dbSNP:rs141524540).
FT                                {ECO:0000269|PubMed:11133745}.
FT                                /FTId=VAR_025976.
FT   VARIANT     444    444       A -> V (in OS; found in patients with an
FT                                atypical form of severe combined
FT                                immunodeficiency/Omenn syndrome;
FT                                dbSNP:rs199474685).
FT                                {ECO:0000269|PubMed:11133745}.
FT                                /FTId=VAR_025977.
FT   VARIANT     449    449       R -> K (in dbSNP:rs4151031).
FT                                /FTId=VAR_029262.
FT   VARIANT     454    454       L -> Q (in OS; dbSNP:rs199474677).
FT                                {ECO:0000269|PubMed:21624848}.
FT                                /FTId=VAR_067274.
FT   VARIANT     474    474       R -> C (probable disease-associated
FT                                mutation found in a patient with
FT                                relatively late onset of infections and
FT                                isolated T-cell lymphopenia; also found
FT                                in a patient with T and B cell
FT                                immunodeficiency and progressive
FT                                multifocal leukoencephalopathy; decreases
FT                                recombination activity; no effect on
FT                                protein abundance; dbSNP:rs199474678).
FT                                {ECO:0000269|PubMed:20956421,
FT                                ECO:0000269|PubMed:28216420}.
FT                                /FTId=VAR_067275.
FT   VARIANT     474    474       R -> H (in OS; found in patients with an
FT                                atypical form of severe combined
FT                                immunodeficiency/Omenn syndrome;
FT                                dbSNP:rs199474686).
FT                                {ECO:0000269|PubMed:11133745}.
FT                                /FTId=VAR_025978.
FT   VARIANT     507    507       R -> W (in CHIDG and OS; found in
FT                                patients with an atypical form of severe
FT                                combined immunodeficiency/Omenn syndrome;
FT                                reduced recombination activity when
FT                                associated with H-737;
FT                                dbSNP:rs104894298).
FT                                {ECO:0000269|PubMed:11133745,
FT                                ECO:0000269|PubMed:18463379}.
FT                                /FTId=VAR_025979.
FT   VARIANT     522    522       W -> C (in OS; also found in patients
FT                                with an atypical form of severe combined
FT                                immunodeficiency/Omenn syndrome;
FT                                dbSNP:rs193922461).
FT                                {ECO:0000269|PubMed:11133745,
FT                                ECO:0000269|PubMed:25516070}.
FT                                /FTId=VAR_025980.
FT   VARIANT     525    525       P -> S (in dbSNP:rs4151032).
FT                                /FTId=VAR_029263.
FT   VARIANT     559    559       R -> S (in T(-)B(-)NK(+) SCID and OS;
FT                                also found in a patient with an atypical
FT                                form of severe combined immunodeficiency/
FT                                Omenn syndrome; decreased recombination
FT                                activity; dbSNP:rs199474681).
FT                                {ECO:0000269|PubMed:11133745,
FT                                ECO:0000269|PubMed:11520796,
FT                                ECO:0000269|PubMed:19912631}.
FT                                /FTId=VAR_025981.
FT   VARIANT     561    561       R -> C (in OS; dbSNP:rs104894285).
FT                                {ECO:0000269|PubMed:9630231}.
FT                                /FTId=VAR_008890.
FT   VARIANT     561    561       R -> H (in OS; dbSNP:rs104894284).
FT                                {ECO:0000269|PubMed:9630231}.
FT                                /FTId=VAR_008889.
FT   VARIANT     612    612       H -> R (found in a patient with an
FT                                atypical form of combined
FT                                immunodeficiency; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25516070}.
FT                                /FTId=VAR_078307.
FT   VARIANT     624    624       R -> C (in OS; dbSNP:rs199474688).
FT                                {ECO:0000269|PubMed:11133745}.
FT                                /FTId=VAR_025982.
FT   VARIANT     624    624       R -> H (in T(-)B(-)NK(+) SCID; decreased
FT                                recombination activity;
FT                                dbSNP:rs199474680).
FT                                {ECO:0000269|PubMed:19912631,
FT                                ECO:0000269|PubMed:8810255}.
FT                                /FTId=VAR_007803.
FT   VARIANT     669    669       E -> G (in OS; dbSNP:rs199474689).
FT                                {ECO:0000269|PubMed:11133745}.
FT                                /FTId=VAR_025983.
FT   VARIANT     699    699       R -> W (in OS; also in a patient with
FT                                multiple autoimmune disorders;
FT                                dbSNP:rs199474676).
FT                                {ECO:0000269|PubMed:21771083}.
FT                                /FTId=VAR_067276.
FT   VARIANT     722    722       E -> K (in T(-)B(-)NK(+) SCID; decreased
FT                                recombination activity;
FT                                dbSNP:rs28933392).
FT                                {ECO:0000269|PubMed:8810255}.
FT                                /FTId=VAR_007804.
FT   VARIANT     737    737       R -> H (in OS and CHIDG; reduced
FT                                recombination activity when associated
FT                                with T-507; dbSNP:rs104894286).
FT                                {ECO:0000269|PubMed:18463379,
FT                                ECO:0000269|PubMed:9630231}.
FT                                /FTId=VAR_008891.
FT   VARIANT     753    753       H -> L (in OS; found in patients with an
FT                                atypical form of severe combined
FT                                immunodeficiency/Omenn syndrome;
FT                                dbSNP:rs199474687).
FT                                {ECO:0000269|PubMed:11133745}.
FT                                /FTId=VAR_025984.
FT   VARIANT     774   1043       Missing (in T(-)B(-)NK(+) SCID; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:8810255}.
FT                                /FTId=VAR_078308.
FT   VARIANT     778    778       R -> Q (in CHIDG; reduced recombination
FT                                activity; dbSNP:rs121918569).
FT                                {ECO:0000269|PubMed:18463379}.
FT                                /FTId=VAR_045958.
FT   VARIANT     820    820       K -> R (in dbSNP:rs2227973).
FT                                /FTId=VAR_008892.
FT   VARIANT     841    841       R -> W (in T-CMVA; also found in a
FT                                patient with an atypical form of severe
FT                                combined immunodeficiency /Omenn
FT                                syndrome; dbSNP:rs104894287).
FT                                {ECO:0000269|PubMed:16276422}.
FT                                /FTId=VAR_025985.
FT   VARIANT     855    855       N -> I (probable disease-associated
FT                                mutation found in a patient with severe
FT                                combined immunodeficiency with maternal
FT                                fetal engraftment; dbSNP:rs199474690).
FT                                {ECO:0000269|PubMed:11133745}.
FT                                /FTId=VAR_025986.
FT   VARIANT     880    880       E -> K (in dbSNP:rs4151033).
FT                                /FTId=VAR_020114.
FT   VARIANT     885    885       L -> R (in OS; dbSNP:rs199474691).
FT                                {ECO:0000269|PubMed:10606976}.
FT                                /FTId=VAR_008893.
FT   VARIANT     887    887       D -> N (in dbSNP:rs4151034).
FT                                /FTId=VAR_029264.
FT   VARIANT     897   1043       Missing (in T(-)B(-)NK(+) SCID; also
FT                                found in patients with an atypical form
FT                                of severe combined immunodeficiency/Omenn
FT                                syndrome; loss of recombination activity;
FT                                unknown pathological significance).
FT                                {ECO:0000269|PubMed:11520796,
FT                                ECO:0000269|PubMed:25516070,
FT                                ECO:0000269|PubMed:8810255}.
FT                                /FTId=VAR_078309.
FT   VARIANT     912    912       Y -> C (in OS; dbSNP:rs104894290).
FT                                {ECO:0000269|PubMed:9630231}.
FT                                /FTId=VAR_008894.
FT   VARIANT     938   1043       Missing (in T(-)B(-)NK(+) SCID; decreased
FT                                recombination activity).
FT                                {ECO:0000269|PubMed:8810255}.
FT                                /FTId=VAR_078310.
FT   VARIANT     975    975       R -> Q (in OS; dbSNP:rs150739647).
FT                                {ECO:0000269|PubMed:11133745}.
FT                                /FTId=VAR_025987.
FT   VARIANT     975    975       R -> W (in CHIDG; reduced recombination
FT                                activity; dbSNP:rs121918570).
FT                                {ECO:0000269|PubMed:18463379}.
FT                                /FTId=VAR_045959.
FT   VARIANT     981    981       Q -> P (in T-CMVA; dbSNP:rs104894288).
FT                                {ECO:0000269|PubMed:16276422}.
FT                                /FTId=VAR_025988.
SQ   SEQUENCE   1043 AA;  119097 MW;  5417A7413DA8CB65 CRC64;
     MAASFPPTLG LSSAPDEIQH PHIKFSEWKF KLFRVRSFEK TPEEAQKEKK DSFEGKPSLE
     QSPAVLDKAD GQKPVPTQPL LKAHPKFSKK FHDNEKARGK AIHQANLRHL CRICGNSFRA
     DEHNRRYPVH GPVDGKTLGL LRKKEKRATS WPDLIAKVFR IDVKADVDSI HPTEFCHNCW
     SIMHRKFSSA PCEVYFPRNV TMEWHPHTPS CDICNTARRG LKRKSLQPNL QLSKKLKTVL
     DQARQARQHK RRAQARISSK DVMKKIANCS KIHLSTKLLA VDFPEHFVKS ISCQICEHIL
     ADPVETNCKH VFCRVCILRC LKVMGSYCPS CRYPCFPTDL ESPVKSFLSV LNSLMVKCPA
     KECNEEVSLE KYNHHISSHK ESKEIFVHIN KGGRPRQHLL SLTRRAQKHR LRELKLQVKA
     FADKEEGGDV KSVCMTLFLL ALRARNEHRQ ADELEAIMQG KGSGLQPAVC LAIRVNTFLS
     CSQYHKMYRT VKAITGRQIF QPLHALRNAE KVLLPGYHHF EWQPPLKNVS SSTDVGIIDG
     LSGLSSSVDD YPVDTIAKRF RYDSALVSAL MDMEEDILEG MRSQDLDDYL NGPFTVVVKE
     SCDGMGDVSE KHGSGPVVPE KAVRFSFTIM KITIAHSSQN VKVFEEAKPN SELCCKPLCL
     MLADESDHET LTAILSPLIA EREAMKSSEL MLELGGILRT FKFIFRGTGY DEKLVREVEG
     LEASGSVYIC TLCDATRLEA SQNLVFHSIT RSHAENLERY EVWRSNPYHE SVEELRDRVK
     GVSAKPFIET VPSIDALHCD IGNAAEFYKI FQLEIGEVYK NPNASKEERK RWQATLDKHL
     RKKMNLKPIM RMNGNFARKL MTKETVDAVC ELIPSEERHE ALRELMDLYL KMKPVWRSSC
     PAKECPESLC QYSFNSQRFA ELLSTKFKYR YEGKITNYFH KTLAHVPEII ERDGSIGAWA
     SEGNESGNKL FRRFRKMNAR QSKCYEMEDV LKHHWLYTSK YLQKFMNAHN ALKTSGFTMN
     PQASLGDPLG IEDSLESQDS MEF
//
